Development of an automated platform for the optimal production of glycoconjugate vaccines expressed in Escherichia coli

Development of an automated platform for the optimal production of glycoconjugate vaccines expressed in Escherichia coli

Abstract Protein Glycan Coupling Technology (PGCT) uses purposely modified bacterial cells to produce recombinant glycoconjugate vaccines. This vaccine platform holds great potential in this context, namely due to its modular nature, the simplified production process in comparison to traditional che...

Full description

Bibliographic Details
Main Authors: Jasmin J. Samaras, Marta Mauri, Emily J. Kay, Brendan W. Wren, Martina Micheletti
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Microbial Cell Factories
Subjects:
Automation
Screening studies
PGCT
Bioconjugation
Glycoconjugate vaccine
Pneumococcal vaccine
Online Access:https://doi.org/10.1186/s12934-021-01588-1

Internet

https://doi.org/10.1186/s12934-021-01588-1

Similar Items